For the Inventor, By the Inventor

Enter assignee name

Alpharetta, GA, United States of America

Atherogenics, Inc.

USPTO Granted Patents = 25

% Expired Patents = 80.0

Forward Citations = 286

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Charles Q Meng (13 out of 15 patents)

James A Sikorski (8 out of 130 patents)

Patricia K Somers (8 out of 9 patents)

4. M David Weingarten (5 out of 9 patents)

5. Uday Saxena (4 out of 26 patents)

6. Liming Ni (4 out of 4 patents)

7. Lee K Hoong (4 out of 4 patents)

8. Jayraz Luchoomun (3 out of 3 patents)

9. Russell M Medford (3 out of 16 patents)

10. Kimberly J Worsencroft (2 out of 2 patents)

11. Mitchell Glass (2 out of 2 patents)

12. David B Edwards (2 out of 2 patents)

13. R Daniel Beauchamp (1 out of 4 patents)

14. Signe Erickson Varner (1 out of 13 patents)

15. Charles A Kunsch (1 out of 17 patents)

Core Competencies:

VCAM-1

Probucol

Cholesterol

Cytoprotective

Oxidative Stress

Antioxidants

Transplant Rejection

Chalcone Derivatives

Dithiocarbamates

Ethers

Esters

Hyperproliferative Conditions

25 patents: Sort by Forward Citations

1. 7375252 - Compounds and method for the inhibition of the expression of VCAM-1 (2008-05-20),

2. 7371895 - Salt forms of poorly soluble probucol esters and ethers (2008-05-13),

3. 7294737 - Process of preparing esters and ethers of probucol and derivatives thereof (2007-11-13),

4. 7273948 - Process of preparing esters and ethers of probucol and derivatives thereof (2007-09-25),

5. 7247714 - Protection against oxidative stress and inflammation by a cytoprotective response element (2007-07-24),

6. 7202247 - 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders (2007-04-10),

7. 7183317 - Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality (2007-02-27),

8. 7173129 - Sulfonamide-substituted chalcone derivatives and their use to treat diseases (2007-02-06),

9. 7094801 - Chalcone derivatives and their use to treat diseases (2006-08-22),

10. 7087645 - Compounds and methods for treating transplant rejection (2006-08-08),

11. 7078431 - 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders (2006-07-18),

12. 7071158 - Antioxidant enhancement of therapy for hyperproliferative conditions (2006-07-04),

13. 6960683 - Salt forms of poorly soluble probucol esters and ethers (2005-11-01),

14. 6887712 - Methods and compositions to lower plasma cholesterol levels (2005-05-03),

15. 6881860 - Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality (2005-04-19),

Company Overview

Atherogenics, Inc. is a biotechnology company based in Alpharetta, Georgia, focused on the development of innovative therapies for cardiovascular diseases. The company specializes in research aimed at understanding and addressing the underlying mechanisms of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. Through its advanced research initiatives, Atherogenics seeks to create effective treatments that can improve patient outcomes and enhance cardiovascular health.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

25 Patents

#26 in Alpharetta, GA

#256 in Georgia

#13,364 in US

#25,710 in the World

Alpharetta, GA, United States of America

Atherogenics, Inc.

Forward Citations = 286

21 inventors:

Charles Q Meng (13 out of 15 patents)

James A Sikorski (8 out of 130 patents)

Patricia K Somers (8 out of 9 patents)

4. M David Weingarten (5 out of 9 patents)

5. Uday Saxena (4 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Atherogenics, Inc.. Retrieved from https://idiyas.com/company/atherogenics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…